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SUMMARY 
Background 
A significant proportion of cases of acute liver failure (ALF) do not have an identifiable cause; so called 
“non A-E”, “non-A, non B, non C”, “seronegative” or “indeterminate” hepatitis. However, this entity is 
clinically not well described.  
Aim 
To collate the known incidence and outcomes in indeterminate hepatitis. This systematic review sought 
to identify potential aetiologies that ought to be considered, and identify likely future objectives in 
classification and treatment strategies for indeterminate hepatitis.  
Methods 
Literature review to determine aetiological factors, prevalence and outcomes relating to indeterminate 
hepatitis.  
Results 
There is significant heterogeneity within the reported cases of indeterminate hepatitis in the literature. 
Some of the potential infective aetiologies which are reviewed here include; parvovirus B19 (PVB19), 
herpes simplex virus (HSV), Toga-Like Virus and the Annelloviridae (including SEN-V).  Interestingly, this 
condition predominately affects middle aged women, with subacute progression of the liver failure. In 
addition, the prognosis of indeterminate hepatitis is poor, with reduced spontaneous survival compared 
with other causes of acute liver failure and increased need for emergency liver transplantation.  
 
Conclusions 
Whilst various pathological processes have been implicated in the development of indeterminate 
hepatitis, the specific cause remains elusive. There is an urgent need for general consensus on a specific 
definition and exclusion of confounding aetiologies with coordinated multicentre investigation of this 
rare condition to identify aetiology and develop therapies to reduce the significant mortality and need 
for emergency liver transplantation associated with this condition. 
  
Introduction 
Acute liver failure (ALF) is a rare and life-threatening condition occurring in patients without pre-existing 
liver disease. The clinical presentation may be rapidly progressive, or insidious with evidence of jaundice, 
coagulopathy and deranged liver enzymes. The development of clinically apparent hepatic 
encephalopathy differentiates those patients with severe acute liver injury (ALI) from patients with ALF1. 
Acute liver failure is associated with significant morbidity and mortality1. The clinical course and outcome 
depends upon the underlying aetiology, age of the patient, the period of time over which the disease 
develops, the extent of liver damage (which are all interrelated) and early institution of supportive care. 1 
The most common cause of ALF in the United Kingdom, USA and some parts of Europe is paracetamol 
(acetaminophen) overdose, which may be taken with suicidal intent or follow accidental consumption of 
excess amounts over time. Elsewhere, viral hepatitis is the most common aetiological agent. However, a 
significant proportion of acute liver failure cases do not have an identifiable cause; so called non A-E, 
seronegative or indeterminate hepatitis. Several studies have proposed the existence of hepatotrophic 
agents beyond those currently recognised, and others have implicated the role of hepatotoxic drugs in 
leading to this clinical syndrome. Previously, GB Virus C 2, hepatitis G Virus3 and TT Virus (TTV)4 have all 
been suggested as pathogenic agents, however true causation has never been substantiated6-8. In this 
review, we discuss the potential aetiological agents, clinical manifestations, treatments and clinical 
outcomes in non A-E, seronegative or indeterminate ALF, identifying significant gaps in current 
understanding of many areas of this rare condition with the aim to facilitate future studies.  
Methods 
This review was conducted according to PRISMA5 statement guidelines. MEDLINE (OvidSP), PubMed, EASL 
(European Association for the Study of Liver) and AASLD (American Association for the Study of Liver 
Diseases) archives were searched for studies in acute or fulminant, hepatic or liver failure using the terms 
“non-A non-B” “non-A, non-B, non-C”, “seronegative hepatitis”, “non A-E” and “indeterminate” hepatic 
or liver failure. This was performed electronically to include all English language publications from 1970. 
The searches were limited to patients over 18 years of age. One investigator (PNB) performed an initial 
screen of the all relevant titles, to exclude duplicates and non-relevant articles. The search was then 
subsequently repeated by two investigators (PNB, MD) whereby each abstract was reviewed and relevant 
articles selected (Figure 1).  
Nomenclature 
There is widespread variability in the nomenclature used both in clinical practice and research studies to 
describe causes of acute liver failure not identified by standard diagnostic tests. Historically this disease 
entity was labelled non-A, non-B hepatitis, and as new viruses were identified non A-E hepatitis became 
the preferred terminology (Figure 2). This nomenclature suggests the aetiological agent for this condition 
is an as yet unidentified hepatotropic virus. More recently, the term ‘seronegative hepatitis’ has also been 
used. This terminology recognises the possibility of uncharacterised autoimmune or immune mediated 
liver injury. Latterly ‘indeterminate hepatitis’ has been favoured when the cause of ALF cannot be 
identified, perhaps covering all potential pathogenic mechanisms of liver injury. Therefore ‘indeterminate 
hepatitis’ will be the preferred term throughout this review.  
O’Grady and colleagues6 proposed modification of the definition for acute liver failure based on the time 
between jaundice and the development of hepatic encephalopathy: “hyperacute liver failure” occurs 
when encephalopathy develops within 7 days of the onset of jaundice, ‘acute liver failure” when 
encephalopathy develops within 8-28 days from jaundice and ‘subacute liver failure” pertains to 
individuals with a more insidious onset of encephalopathy, developing within 5-12 weeks of the onset of 
jaundice. Hyperacute cases of liver failure are most commonly caused by paracetamol hepatotoxicity; is 
more often complicated by the development of cerebral oedema and paradoxically have the best 
outcomes. In contrast, indeterminate hepatitis commonly causes subacute liver failure, which can be 
difficult to differentiate clinically from decompensated liver cirrhosis or acute on chronic liver failure, 
requiring the physician to have a high degree of clinical suspicion. Such cases have poor spontaneous 
survival rates and are major indications for emergency liver transplantation. As previously indicated 
encephalopathy differentiates acute liver failure from cases with acute severe liver injury: these latter 
cases usually survive spontaneously, but clinical models to predict the development of encephalopathy 
are poorly developed. 
Epidemiology 
As discussed above, a significant proportion of patients with acute liver failure have no specific cause 
identified using currently available diagnostic techniques i.e. indeterminate ALF. A number of centres, 
predominantly from the Western world, have reported the number of patients diagnosed with 
indeterminate ALF (Table 1 and Figure 4). In total; the studies included 5, 027 cases of acute liver failure, 
with 689 (~20%) incidents of indeterminate causation. There is some inherent heterogeneity between the 
studies including access to specialist referral units and particular serological tests; therefore the numbers 
should be interpreted with caution. It is well recognised that indeterminate acute liver failure is more 
common in the paediatric than adult population, however a detailed review of the paediatric literature is 
out with the scope of this review.  
 
  
Potential Causative Factors of indeterminate hepatitis (Figure 3). 
Parvovirus 
Parvovirus B19 (PVB19) is commonly recognised as a self-limiting cause of acute hepatitis that usually has 
an indolent course and significant morbidity and mortality in paediatric patients. However, parvovirus is 
less common in the adult population. Huang7 reported a case of active infection in an immunocompetent 
female patient. The infection was acquired from her child. The patient had significant transaminase 
elevation with coagulopathy and jaundice but no encephalopathy and went on to make an unremarkable 
recovery with supportive care. Ho8 also described a case of parvovirus infection in an immunocompetent 
woman of Chinese origin who presented with significant transaminitis, jaundice and ascites. Liver biopsy 
was remarkable for scattered regenerative features but absence of fibrosis or lobular hepatitis. A bone 
marrow sample demonstrated large pro-erythrocytes containing nuclear inclusions and a paucity of 
mature erythroid precursors. Both IgM and IgG were positive for PVB19 infection, consistent with acute 
infection. In this case, infection was also self-limiting. In addition, Langnas9 also proposed parvovirus B19 
as a causative agent in a small case series of acute liver failure, all of which were associated with aplastic 
anaemia. Quite how parvovirus elicits a hepatotoxic effect is not completely understood but may relate 
to caspase 3-mediated apoptosis.10 Adding parvovirus B19 IgM to an acute hepatitis screen may facilitate 
detection of unrecognised cases. 
SEN Virus 
SEN virus (SENV) is a relatively recently characterised, single-stranded DNA-virus of the Annelloviridae 
family and has been suggested as a potential causative agent of indeterminate hepatitis. The virus was 
named after the initials of the patient in whom it was first identified, who was also infected with human 
immunodeficiency virus. In 2013, Rizvi assessed the prevalence of SENV in cases of both acute and chronic 
hepatitis in an Indian population. 11 Within a population of 135 individuals with acute and chronic hepatitis 
they identified SENV in 34 individuals (25.2%). There were 3 patients with acute liver failure, all positive 
for SENV-H genotype. In contrast, Umemura provided robust evidence against SENV being a potential 
cause of indeterminate acute liver failure demonstrating the presence of SENV in 8% of 99 cases of acute 
liver failure from the USA, whilst not a single incident case within the group of patients of liver failure due 
to indeterminate hepatitis was identified.12 
More recently, further attempts to identify the presence of annelloviridae viruses in pathogenesis of 
indeterminate hepatitis have been undertaken using metagenomic techniques; however, once again 
there was no evidence to substantiate causality. 13 
 
Herpes simplex virus 
Herpes simplex virus (HSV) hepatitis is an uncommon complication of HSV infection, which may result in 
acute liver failure. It represents less than 1% of all ALF cases and less than 2% of all viral causes of ALF14 
Acute HSV hepatitis is characterised by massive hepatocellular necrosis often without the well recognised 
mucocutaneous lesions. It is most prevalent in the immunosuppressed or during pregnancy, although one 
review proposed an incidence of ALF within an apparent immunocompetent cohort of 25% 15. Levitsky 14 
suggested that within a cohort of indeterminate hepatitis, 4 patients had evidence of acute HSV infection. 
Two of these individuals underwent emergency liver transplantation for ALF with concomitant antiviral 
therapy, despite this however 1 individual died. Both other acute liver failure patients died within 48 hours 
despite antiviral treatment. 
Al-Midani16 described two cases of acute liver failure secondary to HSV. Both these cases occurred in the 
context of immunosuppression post-renal transplantation. Both individuals were HSV-naïve and 
developed features of hyper-acute liver failure, with one of the patients dying of multiorgan failure and 
one surviving with aciclovir and immunoglobulin therapies. HSV serology should be performed and 
consideration given to empirical use of aciclovir before the results are available in patients with 
indeterminate acute liver failure especially during pregnancy, early puerperium or in immunosuppressed 
patients 17. 
Togavirus-Like Particles 
Togavirus-like particles were previously detected in the native livers of almost 40% (n = 7) of patients 
transplanted for indeterminate hepatitis in a single UK centre.18,19 These particles were not detected in 
the livers of patients transplanted for other causes of ALF, chronic liver disease or in healthy livers. Five 
patients with togavirus-like particles detected in their native liver developed early haemorrhagic hepatic 
failure post-transplant; the particles were again detected in all subsequent liver grafts, at a higher level 
than in the native liver.  
Occult metabolic and genetic disorders 
Occult metabolic and genetic disorders are more likely to be a factor in indeterminate acute liver failure 
in the paediatric population compared with the adult population. Urea cycle defects may cause acute liver 
failure in children; however, their possible causative role in adult indeterminate ALF is not well defined. It 
is important to consider these diagnoses, as rapid treatment may preclude the need for liver 
transplantation. These conditions are particularly important to consider in apparent ‘repeated’ 
indeterminate cases of severe acute liver injury or failure in young adults. 
In a Caucasian cohort of patients with indeterminate hepatitis, a strong genetic preponderance was 
reported in individuals with the homozygous haplotype HLA A1-B8-DR3, conferring a relative risk of 9.7 
times that of a control population of developing acute liver failure. The authors suggest that disordered 
MHC-restricted presentation of viral peptides and enhanced elimination of infected hepatocytes may 
underpin the pathogenesis. This genetic combination generally renders an individual C4 deplete, in 
addition to other aberrant innate immune coordination. Furthermore, homozygosity for this haplotype 
may be associated with non-specific perturbation of immune responses to a range of potentially 
hepatotoxic agents (viral and others), and exceptional susceptibility to the development of lethal liver 
injury. 20 
Undetected paracetamol overdose 
The measurement of paracetamol (acetaminophen) adducts in cases of indeterminate ALF has recently 
been the subject of debate and interest. Paracetamol – protein adducts are formed when NAPQI binds 
with the amino acid cysteine in cellular proteins after large dose paracetamol ingestion, and are released 
into the peripheral circulation as a consequence of hepatocyte necrosis, where they can then be detected. 
Khandelwal’s study confirms and extends the previous reports21 regarding the use of paracetamol - 
protein adduct measurement in the diagnostic evaluation of patients with acute liver failure. In this large 
data set using a refined assay method, paracetamol - protein adducts were detected in 95% of patients 
with clinically defined paracetamol overdose. In addition, nearly 19% of patients with acute liver failure 
classified as indeterminate had adducts detectable suggesting occult paracetamol toxicity not identified 
by experienced investigators using current diagnostic techniques.22 However, these patients also had 
some clinical features and biochemical changes that might be suggestive of paracetamol overdose. A 
rapid, point of care test for paracetamol adducts has recently been developed by Roberts and colleagues23 
and will likely prove to be a valuable diagnostic adjunct in assessment of cases of indeterminate hepatitis 
where concerns persist of occult paracetamol ingestion. Detection of paracetamol overdose is important 
as a specific antidote is available, the clinical course is different and alternative criteria for transplantation 
are applied.  
 
Haemophagocytic lymphohistiocytosis (HLH) 
There have now been several case reports of haemophagocytic lymphohistiocytosis (HLH) causing acute 
liver failure, often being identified late in patients receiving an earlier diagnosis of indeterminate ALF.24,25 
HLH can be a primary or acquired disorder of uncontrolled immune regulation.  HLH has a variable clinical 
spectrum, but typically presents with high fever, hepatosplenomegaly, cytopaenia, coagulation 
abnormalities, histopathologic evidence of haemophagocytosis, and fatal multiple organ failure. 26 Liver 
injury is a common complication of HLH. Previous studies suggest that up to 85% of adult patients with 
secondary HLH have elevated transaminases and 50% have hyperbilirubinaemia. ALF is a rare presenting 
feature but often evolves with progression of multi-organ involvement. 27 Previously, HLH was considered 
a disease of childhood, however adult case series have begun to emerge, 28,29 with a single transplant 
centre24 identifying 3 cases in an adult cohort in a single year. The true incidence in adults is unknown. 
Diagnostic criteria have been suggested for the paediatric population (Table 2).30 These have not been 
validated in adult patients; however they may provide a diagnostic framework for consideration of 
potential cases.  
Unrecognised idiosyncratic drug reactions and environmental toxins 
Drug-induced liver injury (DILI) is a rare complication of many commonly prescribed drugs. It can therefore 
be difficult to ascertain whether a patient with DILI is in fact a patient with indeterminate acute liver 
failure who also happens to be taking a potentially hepatotoxic drug. Several causality scoring systems are 
described, but are rarely applied in clinical practice and an objective, reproducible clinical method of 
assessing drug=induced liver injury causality is still required 31. There has been increasing interest in the 
recognition of DILI, with the establishment of a number of international corsortia specifically investigating 
this important topic, and as we learn more about DILI, more cases of apparent indeterminate hepatitis 
may in fact be attributed to DILI. A specific biomarker for DILI would allow clinicians to differentiate 
between unrecognised drug-induced liver injury and indeterminate acute liver failure, but has yet to be 
developed. 
Environment and occupational agents and toxins have been proposed as a potential cause of 
indeterminate ALF. A high index of suspicion must be maintained to recognise an environmental or 
occupational agent as the cause of ALF. Tetrachloroethylene has been reported to cause acute liver 
failure, with one patient recovering with steroids and plasmapheresis 32. This presentation was similar to 
that of drug-induced liver injury, but in many patients history of exposure to this toxin may not be 
available. Several solvents are also implicated in causing acute liver injury, and again if exposure to these 
agents are not reported or identified, the patient may be mislabeled as having indeterminate ALF. These 
solvents include dimethylformamide, dimethylacetamide and trichloroethylene33. In a study of the latter, 
10% of workers exposed to tricholoroethylene became jaundiced with massive hepatocyte necrosis34  
Unrecognised or seronegative autoimmune disease 
Undiagnosed autoimmune disease may contribute to the cause of ‘indeterminate’ acute liver failure. 
Some cases of apparent indeterminate ALF occur in young females with history of other autoimmune 
disease and suggestive features of autoimmune hepatitis on histological analysis. The American Acute 
Liver Failure Study Group (ALFSG) investigated 72 patients with a diagnosis of indeterminate hepatitis who 
had a biopsy or explant available for review. The reviewing pathologist was blinded to all clinical 
information, and diagnosed autoimmune liver disease on the basis of histological findings in 58% of 
patients. However, 50% of these had detectable anti-nuclear antibody (ANA) (titre not reported), 63% 
detectable ANA+/-ASMA and mean ALT 1134 IU/L35.  In a population of predominantly young Caucasian 
females, these clinical features alone may have pointed towards a potential diagnosis of AIH.  
In a cohort of 73 acute liver failure patients of varying aetiologies, Bernal demonstrated the presence of 
features of autoimmunity, including antibodies to soluble liver antigen (Anti-SLA) and other non-organ 
specific antibodies (NOSA). Autoantibodies were absent in paracetamol-related cases and present in 23 
of 53 of non-paracetamol cases; anti-SLA (n=16), ANA (6), ASM (4) and AMA (1). There were 16 cryptogenic 
cases; 5 of whom had anti-SLA. AIH scores classified 50% of cryptogenic cases as “probable autoimmune 
hepatitis”. 36 
Re-evaluation of aetiology 
The American Liver Failure Study Group (ALFSG) recently re-evaluated 314 cases of patients who had 
previously been given a diagnosis of indeterminate ALF 37. Patient samples were retrospectively tested for 
paracetamol adducts, occult viral sequences by microarray analysis and deep sequencing; if available, liver 
histology was also re-reviewed. As a result of these further tests, 49% of patients (49% of 294 with 
complete information) received a new diagnosis; of these, 43 patients were diagnosed as acute liver 
failure due to paracetamol overdose, 33 autoimmune hepatitis, 7 viral cases (1 PVB19, HBV, EBV, VZV and 
3 HSV), and 23 drug-induced liver injury using the DILI network model. In those patients in whom an 
alternative diagnosis was not made, the diagnosis was ‘indeterminable’ if key diagnostic information was 
missing, and ‘truly indeterminate’ if complete diagnostic information was available. 31% were defined as 
truly indeterminate, making up just 3.3.% of acute liver failure cases in the ALFSG registry overall. This 
figure is lower than that reported in other studies, suggesting that diagnostic techniques as described 
above do need to be more widely adopted to ensure a correct diagnosis is made.  
 
Clinical features 
Indeterminate hepatitis usually results in subacute liver failure, with the symptoms typically present 
greater than 4 weeks before the development of encephalopathy. There is a female preponderance 
reported in all cases series, with a bimodal age distribution. Table 1 records the percentages of patients 
with indeterminate liver failure contributing to reported cohorts of patients with ALF. The highest 
reported percentage of patients with indeterminate acute liver failure was reported in Sudan13, however 
their access to certain diagnostic techniques may be limited. A group from China also reported a higher 
percentage of patients with indeterminate acute liver failure compared with other studies20, however it 
must be borne in mind that this study included paediatric patients.  
Prodromal symptoms are non-specific, including fatigue, myalgia and nausea. Often these symptoms can 
be mistaken for a viral prodrome. Biochemically, these patients demonstrate lower transaminases and 
higher bilirubin levels, similar to other causes of subacute ALF and in contrast with the high transaminases 
and lower bilirubin levels seen in hyperacute liver failure, especially paracetamol toxicity. Other clinical 
features include a lesser degree of coagulopathy, and less renal failure and acidosis when compared with 
paracetamol toxicity.  
The American Liver Failure Study Group have previously described the demographics of patients 
registered with indeterminate hepatitis on the ALFSG Adult Registry between 1998 and 201438. The main 
findings are summarised in Table 3. In a separate cohort of 140 patients with indeterminate (seronegative) 
acute liver failure, Wigg observed similar clinical features: 59% of the cohort were female. Of those 
proceeding to transplantation, the mean age was 40 years, and 86% were Caucasian. 49% had grade 3-4 
hepatic encephalopathy prior to transplantation39. 
Association with aplastic anaemia 
Indeterminate hepatitis is the most common cause of ALF with associated aplastic anaemia40. The 
presence of aplastic anaemia increases the mortality associated with acute liver failure and may not 
resolve following transplantation, necessitating post-transplant treatment with immunosuppressive 
therapy or even haematopoietic cell transplantation. The presence of aplastic anaemia raises the 
suspicion that a viral aetiology is the cause for indeterminate disease 9. 
 
Management 
The principle goal of management of acute liver failure (regardless of aetiology) is to achieve metabolic 
and haemodynamic stability to provide optimal conditions for hepatic regeneration and minimisation of 
associated complications. Early identification of individuals with a significantly reduced chance of 
spontaneous survival enhances the provision of successful emergency liver transplantation. The 
treatment is generally founded on the basic principles applied to other critically unwell patients, with 
some specific caveats. 41 
Medical management 
Some aetiologies of acute-liver failure have a specific treatment or antidote available. Unfortunately, this 
is not the case for indeterminate hepatitis. Management is therefore supportive, and several guidelines 
are available to advise the general and critical care management of these patients. The main aspects of 
organ specific supportive management as recommended by EASL and AASLD are compared in Table 4.  
 N-acetylcysteine (N-Ac) 
NAC has complex antioxidant and immunological effects that may benefit individuals with non-
paracetamol-related acute liver failure. Stravitz42 demonstrated that interleukin-17 was an independent 
predictor of poor outcome in patients with non-paracetamol ALF;  higher interleukin-17 levels were 
associated with progression of hepatic encephalopathy and decreased with NAC administration. However, 
this survival benefit of N-Ac seems to be limited to those non-paracetamol patients with Grade I-II 
encephalopathy.43 More recently Darweesh44 demonstrated a greater degree of spontaneous recovery in 
NAC treated patients, particularly those with coagulopathy only. A reduction in the development of 
encephalopathy during admission (33% vs 63%; p = 0.02) was observed. However, this cohort did not 
include any individuals with indeterminate liver failure as a diagnosis and consisted principally of viral 
hepatidities, drug-induced variants and pregnancy-related complications. It is therefore difficult to derive 
any significance in the case of indeterminate aetiologies, but many centres will utilise N-Ac in cases of 
indeterminate hepatitis.  
A multi-centre prospective double-blind trial of NAC in patients with non-paracetamol ALF was 
undertaken by the Acute Liver Failure Study Group (ALFSG) 45. The treatment group received NAC via 
infusion for 72 hours. There was no difference in overall survival at 3 weeks in those patients receiving N-
Ac versus placebo. However, transplant free survival was significantly improved in those patients receiving 
NAC, but this benefit was largely confined to those patients with a low coma grade (transplant free survival 
in patients with coma grade I-II; 52% in N-Ac group versus 30% in placebo group). The authors therefore 
cautiously advised that N-Ac be considered for early non-paracetamol ALF but that its use must not delay 
referral to a transplant centre.  
 Corticosteroids 
The use of corticosteroid therapy in acute liver failure has been controversial. A study by Karkhanis46 
suggested that corticosteroids did not improve overall survival or spontaneous survival in drug-induced, 
indeterminate, or autoimmune ALF and were associated with lower survival in patients with the highest 
MELD scores. More recently, a retrospective analysis reviewed the survival in individuals with both acute 
and subacute liver failure in Chongqing, China. They confirmed previous findings whereby those 
individuals with high grade encephalopathy or Model for End-stage Liver Disease (MELD) scores greater 
than 35 did particularly poorly. Nevertheless, they did suggest improved rates of spontaneous survival 
associated with steroid use among patients who had significantly elevated alanine aminotransferase (ALT) 
greater than 30 x the upper limit of normal and coma grade less than 4 with MELD scores less than 35. 
This finding was most significant in those with an illness duration of less than 2 weeks. 47 Unfortunately 
they did not specify outcomes for different aetiologies and it is therefore hard to evaluate any specific 
benefit in indeterminate hepatitis. Given the relative lack of robust evidence in indeterminate liver failure, 
steroid therapy cannot be advocated unless there is significant concern regarding underlying 
autoantibody negative autoimmune hepatitis.  
 
Prognostication and emergency liver transplantation 
The early identification of individuals with acute liver failure and significantly reduced spontaneous 
survival with medical therapy is crucial in identifying candidates for emergency liver transplantation. In 
patients with indeterminate hepatitis on the ALFSG Adult Registry between 1998 and 2013, 57% of 
patients with indeterminate hepatitis were listed for transplant, with a transplant free survival rate of 
27.5% 48. In the remainder of the western world, the spontaneous (transplant free) survival rate for 
indeterminate liver failure is also quoted between 20-25%, in comparison with 65% spontaneous survival 
in patients with paracetamol induced acute liver failure49. 
Various prognostic criteria are applied throughout the world. Common features of these models include 
age and increased severity of liver failure defined by the degree of coagulopathy and jaundice. 41The Kings 
College Criteria have traditionally been used in the UK and elsewhere in the western world to predict poor 
outcome. In patients with a non-paracetamol aetiology such as indeterminate hepatitis, an INR > 6.5 and 
three or more of the following were predictors of a poor outcome: unfavourable cause (not hepatitis A or 
B viral infection), jaundice to encephalopathy time greater than 7 days, age less than 10 or more than 40 
years, INR more than 3.5 and bilirubin more than 300umol/L. In many studies including systematic reviews 
and meta-analyses, these criteria have consistently demonstrated high specificity but lower sensitivity 
and negative predictive value50.  In the UK, the criteria used to list patients for emergency liver 
transplantation have recently been modified 51. These refined criteria recognise the importance in 
distinction between favourable and unfavourable aetiology in prognosis in the sub-group of patients with 
non-paracetamol aetiologies, with indeterminate hepatitis being considered unfavourable. The new 
criteria now allow emergency liver transplant listing of a patient with indeterminate hepatitis in the 
absence of hepatic encephalopathy, recognising that this sign is often a very late development in the 
clinical course of these patients and by the time hepatic encephalopathy has developed the patient may 
be too sick to survive transplant (particularly if encephalopathy has been precipitated by infection).  The 
current UK listing criteria are shown in Table 5.  
In 2012, Wlodzimirow performed a systematic review of newly developed and modified existing 
prognostic models of mortality for acute liver failure 52. This review ultimately identified that although 
many studies describing new models are available, these studies demonstrate methodological and 
reporting limitations, and are not yet suitable for general clinical application. The Model for End Stage 
Liver Disease (MELD) score has been proposed as an alternative to the Kings College Criteria. A recent 
meta-analysis quantitatively assessed and compared their prognostic accuracy in acute liver failure. In 
non-paracetamol causes, the Kings College Criteria demonstrated a sensitivity of 58%, specificity of 74% 
and diagnostic odds ratio of 4.16; MELD demonstrated a sensitivity of 76%, specificity of 73% and 
diagnostic odds ratio of 8.42. This study suggested the MELD may be a better predictor of mortality in 
patients with non-paracetamol acute liver failure. However, studies were limited by multiple factors such 
as small sample sizes, disease heterogeneity and classification (or not) of transplanted patients as non-
survivors. The Acute Liver Failure Study Group recently published a model to predict 21-day transplant 
free survival (not death, the outcome of interest in most prognostic models) in patients with acute liver 
failure. 53 The aetiology of liver injury is a key component of this model, with indeterminate hepatitis again 
considered as an unfavourable aetiology. This model was highly specific but had much reduced sensitivity 
(specificity 95.3%, sensitivity 37.1%, AUC 0.84) in predicting 21-day spontaneous survival, and requires 
validation in external cohorts.  
Emergency Liver Transplantation 
Patients with indeterminate acute liver failure have a reduced spontaneous survival compared with other 
aetiologies. The lack of specific medical therapy results in emergency liver transplantation forming the 
mainstay of treatment in severe cases. Emergency transplantation has resulted in significant improvement 
in survival in patients with indeterminate acute liver failure over several decades 54. Most countries 
operate an organ allocation system that offers patients with acute liver failure the highest priority; most 
cases being transplanted within 48 hours of listing. In contrast with paracetamol induced liver failure, the 
mortality on the waiting list is reduced in cases of indeterminate ALF. The ALFSG recently reported 21 day 
outcomes in patients who were listed for urgent transplantation for a variety of aetiologies. 114 patients 
were listed for indeterminate ALF; 84 (73.6%) proceeded to transplantation, 15 (13.2) died and 15 (13.2%) 
spontaneously survived. These outcomes were significantly different to those reported for patients with 
paracetamol induced acute liver failure; in this cohort, 35.8% (n = 62) proceeded to liver transplantation, 
41 (23.7%) died and 70 (40.5%) spontaneously survived, highlighting the important role emergency 
transplantation has in the management of indeterminate acute liver failure.  
Bernal reported that use of transplantation for non-paracetamol liver failure has increased over time, with 
the proportion of patients undergoing transplantation being higher in non-paracetamol cases compared 
with paracetamol cases54. Survival following transplantation has also increased over time, likely as a result 
of improvements in surgical, medical and intensive care management. However, in the same cohort, no 
improvement in transplant free survival was noted over time. Donnelly also recently reported an increase 
in survival post transplantation for patients with non-paracetamol acute liver failure, with a trend towards 
improvement in transplant free survival also observed 49. There is no doubt that transplantation is the 
only rescue therapy proven to be of benefit in selected patients with severe indeterminate hepatitis, and 
other treatment options are desperately needed so as not to disadvantage those on the elective liver 
transplant waiting list.   
Future therapies and strategies 
Future work and research should focus on developing large international registries of patients with 
indeterminate acute liver failure, which may help to identify population based factors associated with the 
development of the disease, which in turn may point towards a specific aetiological agent or trigger. Such 
registries may also identify common clinical features allowing earlier diagnosis and prognostication.  
“Omic” technologies will likely have a role to play in the future in both the diagnosis and prognosis of 
indeterminate acute liver failure. Metabolomics studies a set of metabolites present in biological fluids, 
and facilitates the discovery of specific metabolic profiles associated with a disease. However, this is a 
technique still early in clinical application and it is unlikely to be used extensively in the near future. 
Sequencing and microarray technology may allow the detection of novel viruses. Such technology has 
already been successful in identifying a virus associated with prostate cancer and novel viral causes of 
SARS 55. Although potential viral causes may be identified this way, demonstrating a true causal 
relationship will be challenging. Whole exome sequencing has been used in the paediatric population to 
identify rare causes of ALF in patients who were otherwise labelled as having an indeterminate cause. 
Causes of ALF identified using this technique include mitochondrial disorders and syndromic cholestasis 
due to NOTCH2 mutations 56. Recently, Somasekar used metagenomic next-generation sequencing 
(mNGS) with confirmatory Nucleic Acid Testing (NATs) in a cohort of 178 patients with indeterminate 
hepatitis. Within this group they identified eight cases of previously unrecognised viral infections. These 
included 4 cases of HSV-1 (with one hepatitis B (HBV) co-infection), in addition to single instances of 
hepatitis B virus, parvovirus B19, human herpes virus-7 (HHV-7) and cytomegalovirus. 57 
 
Conclusions 
The ‘indeterminate’ aetiology is a relatively common cause of acute liver failure in the western world. 
Potential unrecognised causes of this clinical condition include viral agents which are undetected via 
routine screening, missed paracetamol overdose or other drug induced liver injury, and seronegative 
autoimmune disease. It is likely that there is no single causative factor. Medical management is 
supportive, but indeterminate hepatitis has a poor overall outcome with transplantation being the only 
curative option available at present. Further research in this field is desperately required, to identify any 
aetiological agents, develop specific therapy and to reduce the number of patients who require 
emergency liver transplantation. 
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 Tables 
Table 1: Cohort studies of Acute Liver Failure (ALF) with incidence of indeterminate hepatitis reported 
ADULT STUDY COHORT (Country) PERCENTAGE OF PATIENTS WITH 
INDETERMINATE ALF 
Ostapowicz G et al58 
 
 
308 adult patients with ALF (US) 17% 
Wigg et al39 
 
Adult patients with ALF 
(United Kingdom) 
16% 
Mudawi HM et al59 37 patients with ALF 
(Sudan) 
38% 
Areia M et al60 
 
61 cases of ALF  
(Portugal)  
26% 
Adukauskiene D et al61 
 
28 adult patients with ALF  
(Lithuania) 
17.9% 
Canbay A et al62 
 
 
134 adult patients with ALF 
              2002-8  
(Germany) 
20.9% 
Marudanayagam R et al63 1,237 adult patients with ALF 
(United Kingdom) 
15% 
Coilly A et al64 
 
541 adults patients with ALF  
(France) 
13% 
Hadem J et al65 
 
155 adult patients with severe ALI and ALF  
(Germany) 
24% 
Zhao P et al66 
 
177 patients aged > 12 years with ALF 
(China) 
29.38% 
Fabrega E et al67 
 
17 adults patients with ALF  
(Spain) 
24% 
Fujiwara K et al68 
) 
106 adult patients with ALI or ALF 
(Japan) 
22.6% 
Reddy KR et al69 614 adult patients with ALF 
(United States) 
18.6% 
Donnelly MC et al49 1,164 adult patients with ALI and ALF 
(Scotland) 
5.5% 
 
 
 
  
 Table 2. Diagnostic criteria for Haemophagocytic Lymphohistiocytosis (HLH) (adapted from Diagnostic 
and Therapeutic Guidelines for Haemophagocytic Lymphohistiocytosis; Pediat. Blood Cancer 2007)  
The Diagnosis of HLH may be established by  
1. A molecular diagnosis consistent with HLH 
(e.g. Mutations associated with PRF1, UNC13D, STX11) 
 
Or 
2. Presence of 5 of 8 of the following: 
a. Fever (>38.5o for 7 days) 
b. Splenomegaly 
c. Cytopaenias (Affecting at least 2 of the 3 following lineages in peripheral blood) 
1. Haemoglobin (<9g/dL) 
2. Thrombocytopaenia (<100x109/L) 
3. Neutropaenia (<1x109/L) 
 
d. Hypertriglyceridaemia (fasting >2mol/L) and/or hypofibrinogenaemia (<1.5g/l) 
e. Haemophagocytosis  (Bone Marrow, Spleen or Lymph Nodes) 
f. Low or Absent NK activity 
g. Ferritin >500µg/ml 
h. Soluble CD25 >2400U/ml 
 
  
Table 3: Demographics within cohort of indeterminate hepatitis (unpublished data- American Liver 
Failure Study Group (ALFSG)38 and Scottish Liver Transplantation Unit (SLTU)) 
 
Demographics: USALF (n=245, 1998-2014) SLTU (n=105; 1992-2017) 
Age (Years) 39 45 [34 - 57] 
Sex (% Female) 59 70.5% 
Jaundice to coma (Days) 11  
HE grade >3 (%) 48  
ALT (IU) 865 972 [390 - 2095] 
Bilirubin (µmol/l) 361 406 [148 - 515] 
Creatinine (µmol/l)  67 [90 - 176] 
Prothrombin Time (sec)  22 [32 - 45] 
(Continuous data are median and IQR) 
 
 
 
  
Table 4: Comparison of European Association for Study of the Liver (EASL) vs American Association for 
Study of Liver Disease (AASLD) statements on management of acute liver failure (ALF) 
 
 European Association for Study of the 
Liver (EASL) Recommendations 70 
American Association for the Study of 
Liver Disease (AASLD) 
Recommendations 71 
Cardiovascular 
1. Resuscitation with crystalloid (evidence level 
II-1; GR = 1) 
2. Persistent hypotension necessitates critical 
care management with vasoactive agents as 
guided by monitoring (evidence level II-3, 
GR=1) 
3. Norepinephrine is preferable vasopressor 
(evidence level III, GR = 1) 
4. A blood pressure target has not been defined 
in the literature (evidence level III, GR=2) 
5. Hydrocortisone therapy does not reduce 
mortality but does decrease vasopressor 
requirements (evidence level II-1, GR = 1) 
1. Fluid resuscitation and maintenance of 
adequate intravascular volume are 
recommended on presentation in patients 
with ALF. The initial treatment of 
hypotension should be with intravenous 
normal saline (III). 
2. Systemic vasopressor support with agents 
such as norepinephrine should be 
administered in volume-refractory 
hypotension or to ensure adequate CPP. 
Vasopressin or terlipressin can be added to 
norepinephrine in norepinephrine-refractory 
cases, but should be used cautiously in 
severely encephalopathic patients with 
intracranial hypertension (II-1) 
3. Goals of circulatory support in patients with 
ALF are a MAP ≥75 mmHg and CPP 60-80 
mmHg (II) 
Respiratory 
1. Standard sedation and lung protective 
ventilator techniques should be utilised in 
patients with ALF (evidence level II-3, GR = 1) 
2. Avoid of excessive hyper or hypocarbia 
(evidence level III, GR =1) 
3. Regular chest physiotherapy should be 
carried out and ventilator associated 
pneumonia (VAP) avoided (evidence level III, 
GR =1) 
1. Not specified 
Renal 
1. Early institution of renal replacement 
therapy (RRT) should be considered for 
persistent hyperammonaemia, control of 
hyponatraemia and other metabolic 
derangements, fluid balance and 
temperature regulation (evidence level III, 
GR=1) 
2. Anticoagulation of RRT is ambiguous and if 
citrate is utilised should mandate close 
monitoring of metabolic state (evidence level 
II-2, GR=1) 
3. Continuous RRT is preferable to intermittent 
haemodialysis (evidence level III, GR=1) 
1. If dialysis support is needed for acute renal 
failure, it is recommended that a 
continuous mode rather than an 
intermittent mode be used (I). 
Gastrointestinal 
1. Patients with ALF should be considered for 
enteral or parenteral nutrition (evidence 
level II-3, GR=1) 
2. Avoid NG feeding in patients with 
progressive encephalopathy (evidence level 
III, GR=1) 
3. PPI administration should be balanced 
against the risk of VAP and clostridium 
Difficile infection (evidence level Ii-3, GR=1) 
1. Patients with ALF in the ICU should receive 
prophylaxis with H2 blocking agents or 
proton pump inhibitors (or sucralfate as a 
second-line agent) for acid-related 
gastrointestinal bleeding associated with 
stress (I) 
Biochemical/Metabolic 
considerations 
1. Stringent attention to normalisation of 
biochemical abnormalities is warranted in 
ALF (evidence level III, GR=1) 
2. Hypoglycaemia is common in patients with 
ALD and associated with increased mortality 
(evidence level II-3, GR=1) 
1. Metabolic homeostasis must be carefully 
maintained in ALF patients. Overall 
nutritional status as well as glucose, 
phosphate, potassium and magnesium levels 
should be monitored frequently, with 
expeditious correction of derangements (III) 
3. Hyponatraemia is detrimental to outcome 
and should be corrected to maintain 
concentrations of 140-150mmol/l (evidence 
level II-2, GR=1) 
4. Lactate elevation is related to increased 
production and reduced clearance and 
remains a poor prognostic marker. RRT is 
indicated to correct acidosis and metabolic 
disturbances (evidence level II-3, GR=1) 
Infection/SIRS 
1. Prophylactic antibiotics, non-absorbable 
antibiotics and antifungal therapy has not 
been shown to improve survival in ALF 
(evidence level II-2, GR=1) 
2. Early anti-infection treatments should be 
introduced upon appearance of progression 
of hepatic encephalopathy, clinical signs of 
infections, or elements of SIRS (evidence 
level II-3, GR=1) 
3. Antifungal therapy in those with prolonged 
critical care support for multiple organ 
failure should be considered, as guided by 
the use of biomarkers (evidence level II-3, 
GR=1) 
1. Prophylactic antibiotics and antifungals have 
not been shown to improve overall 
outcomes in ALF and therefore cannot be 
advocated in all patients, particularly those 
with mild hepatic encephalopathy (III) 
2. Periodic surveillance cultures are 
recommended to detect bacterial and fungal 
pathogens as early as possible. Antibiotic 
treatment should be initiated promptly 
according to surveillance culture results at 
the earliest sign of active infection or 
deterioration (progression to high grade 
hepatic encephalopathy or elements of the 
SIRS) (III) 
Neurological 
1. Patients with low grade encephalopathy 
should be frequently evaluated for signs of 
deterioration (evidence level III, GR=1) 
2. Patients with Grade 3 or 4 encephalopathy , 
intubation should be undertaken. Regular 
evaluation for signs of intracranial 
hypertension should be performed (evidence 
level III, GR=1) 
3. Trans-cranial doppler is a useful non-invasive 
monitoring tool (evidence level II-3, GR=1) 
4. Invasive intracranial pressure monitoring 
should be considered in a highly selected 
subgroup of patients, who have progressed 
to grade 3 or 4 coma, are intubated and 
ventilated and deemed at high risk of 
Intracranial hypertension (ICH) (evidence 
level II-3, GR=1) 
5. Mannitol or hypertonic saline should be 
administered for surges of ICP with 
consideration for short-term 
hyperventilation. Mild hypothermia and 
indomethacin may be considered in 
uncontrolled ICH (evidence level II-2, GR=1) 
1. In the absence of ICP monitoring, frequent 
(hourly) neurological evaluation is 
recommended to identify early evidence of 
intracranial hypertension (III) 
2. Intracranial pressure monitoring is 
recommended in ALF patients with high 
grade hepatic encephalopathy, in centers 
with expertise in ICP monitoring, in patients 
awaiting and undergoing liver 
transplantation (III) 
3. Patients who progress to high-grade hepatic 
encephalopathy (grade III or IV) should 
undergo endotracheal intubation (III) 
4. In the event of intracranial hypertension, a 
mannitol bolus (0.5-1.0 gm/kg body weight) 
is recommended as first-line therapy; 
however, the prophylactic administration of 
mannitol is not recommended (II-2) 
5. In ALF patients at highest risk for cerebral 
edema (serum ammonia >150 μM, grade 3/4 
hepatic encephalopathy, acute renal failure, 
requiring vasopressors to maintain MAP), the 
prophylactic induction of hypernatremia with 
hypertonic saline to a sodium level of 145-
155 mEq/L is recommended (I) 
Legend; ALD- Alcoholic Liver Disease, ALF- Acute Liver Failure, CPP- Central Pulse Pressure, MAP – Mean Arterial Pressure, NG- Nasogastric,  PPI- 
Proton Pump Inhibitor, SIRS- Systemic Inflammatory Response Syndrome, RRT- Renal Replacement Therapy 
  
 Table 5: Current UK listing criteria for super-urgent liver transplantation 
Legend: ICP- Intracranial Pressure, INR- International Normalised Ratio   
 AETIOLOGY CRITERIA 
CATEGORY 1 Paracetamol pH < 7.25 more than 24 hours after overdose 
and after fluid resuscitation 
CATEGORY 2 Paracetamol Co-existing prothrombin time >100 seconds or 
INR >6.5, and serum creatinine >300 umol/L or 
anuria, and grade 3-4 encephalopathy 
CATEGORY 3 Paracetamol Significant liver injury and coagulopathy 
following exclusion of other causes of 
hyperlactataemia after adequate fluid 
resuscitation: arterial lactate >5mmol/L on 
admission and >4mmol/L 24 hours later in the 
presence of clinical hepatic encephalopthy  
CATEGORY 4 Paracetamol Two of the three criteria from Category 2 with 
clinical evidence of deterioration (eg increased 
ICP, FiO2 >50%, increasing inotrope 
requirements) in the absence of clinical sepsis 
CATEGORY 5 Favourable non-paracetamol (such as acute 
viral hepatitis or ecstasy/cocaine induced ALF) 
The presence of clinical hepatic 
encephalopathy is mandatory and: 
prothrombin time >100 seconds, or INR >6.5, 
or any three from the following: age <10 or >40 
years, prothrombin time > 50 seconds or INR > 
3.5, any grade of hepatic encephalopathy with 
jaundice to encephalopathy time > 7 days, 
serum bilirubin > 300umol/L 
CATEGORY 6 Unfavourable non-paracetamol (such as 
seronegative hepatitis or idiosyncratic drug 
reactions) 
a) Prothrombin time > 100 seconds or 
INR > 6.5 
b)  In the absence of clinical hepatic 
encephalopathy then INR >2 after 
vitamin K repletion is mandatory 
and any two from the following: age 
<10 or > 40 years, prothrombin time 
>50 seconds or INR > 3.5; serum 
bilirubin > 300 umol/L and if 
encephalopathy is present then 
jaundice to encephalopathy time > 
7 days. 
CATEGORY 7 Acute presentation of Wilson disease or Budd-
Chiari syndrome 
A combination of coagulopathy and any grade 
of encephalopathy 
Figures 
Figure 1. Flow diagram of literature search and relevant articles 
Figure 2. Timeline of hepatotrophic virus discovery  
Figure 3. Potentially implicated aetiologies of indeterminate Acute Liver Failure (ALF) 
Figure 4. Cumulative and incident studies of indeterminate acute liver failure by country 
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